Tinidazole

Evidence Level: L5

Predicted Indications: 10

Tinidazole

Pharmacist Assessment Report

Tinidazole: From Giardiasis and Trichomoniasis to Postmenopausal Atrophic Vaginitis

One-Sentence Summary

Tinidazole is an antimicrobial originally used to treat protozoal and anaerobic infections such as giardiasis, amoebiasis, trichomoniasis and bacterial vaginosis. The TxGNN model predicts it may be effective for postmenopausal atrophic vaginitis, but no clinical trials and no publications currently support this specific prediction. The result is a model-only prediction that should be treated as a hypothesis.

Quick Overview

Item	Content
Original Indication	Giardiasis, bacterial vaginosis, vaginitis, vulvitis, vulvovaginitis, amoebiasis due to Entamoeba histolytica, trichomoniasis
Predicted New Indication	Postmenopausal atrophic vaginitis
TxGNN Prediction Score	0.9993
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, tinidazole is a 5-nitroimidazole antimicrobial. Its efficacy in vaginal infections such as bacterial vaginosis and trichomoniasis is established, and the model appears to link it to vaginitis in general.

The prediction score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, such as the approved vaginitis, vulvitis and vulvovaginitis indications, not biological evidence. Atrophic vaginitis after menopause is caused mainly by estrogen deficiency, not infection. An antimicrobial would therefore not be expected to treat the underlying condition. At most it might help with a secondary infection.

Other high-scoring predictions point the same way. The ulceration of vulva, vulvar neoplasm, benign breast conditions (fibrocystic disease, blunt duct adenosis, apocrine adenosis, benign mammary dysplasia) and HIV-related conditions all have weak or no plausible mechanistic rationale. Their scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Clinical Trial Evidence

Currently no related clinical trials are registered for postmenopausal atrophic vaginitis.

For reference, the only registered trial among the other predicted indications (AIDS) is below. It is indirectly relevant at best.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03412071	Not applicable	Unknown	125	Pilot study of four antimicrobial products (3 topical, 1 systemic) on the foreskin microbiome and HIV susceptibility in Ugandan men. It does not test tinidazole for AIDS treatment, and no efficacy data are available.

Literature Evidence

Currently no related literature is available for postmenopausal atrophic vaginitis.

Literature was retrieved only for the AIDS prediction. It mostly concerns tinidazole’s established uses and does not show benefit in HIV.

PMID	Year	Type	Journal	Key Findings
21931875	2011	Cohort	PLoS Negl Trop Dis	Retrospective analysis of 170 HIV-1-infected Japanese men with invasive amoebiasis: clinical features and response to therapy
8442923	1993	Preliminary study	AIDS	Combined tinidazole, thiabendazole and cotrimoxazole versus placebo for AIDS diarrhoea in Zambia
34794678	2022	Review	Pediatr Clin North Am	Amoebiasis and amoebic liver abscess in children, including higher risk in people with HIV/AIDS
19632225	2010	Review	Exp Parasitol	Treatment options and prospects for new drugs against Cryptosporidium and Giardia
35863010	2022	In vitro	Microbiol Spectrum	In vitro activity of 5-nitroimidazole drugs against T. vaginalis clinical isolates
31324206	2019	Trial protocol	Trials	Randomized trial protocol on antimicrobial effects on penile microbiota and HIV susceptibility in Ugandan men
21097745	2010	Case report	Int J STD AIDS	Trichomoniasis presenting as vulval ulceration, fully resolved after oral tinidazole
33121364	2021	Case report	Int J STD AIDS	Successful tinidazole desensitization in a patient with trichomoniasis allergic to metronidazole

India Market Information

Twenty valid single-ingredient registrations are on record. The approved indication text is not available for any of them. Five main registrations are listed below.

Authorization Number	Product Name	Dosage Form	Manufacturer
84533	Fasigyn 500mg Tablet	Strip of 4 tablets	Pfizer Ltd
84516	Fasigyn DS 1000mg Tablet	Strip of 2 tablets	Pfizer Ltd
222759	Tinibid DS 1000mg Tablet	Strip of 6 tablets	Sun Pharmaceutical Industries Ltd
218212	Tinifas 500mg Tablet	Strip of 10 tablets	Cipla Ltd
215735	Tiniba 800mg Infusion	Bottle of 400 ml infusion	Zydus Cadila

Available forms are oral tablets and intravenous infusions. No vaginal formulation appears in the registration data.

Safety Considerations

Contraindication-related conditions (knowledge graph): epilepsy, neutropenia, agranulocytosis, peripheral nervous system disease and peripheral neuropathy. These come from graph associations, not from label text.
Drug Interactions: 161 interactions are recorded, and the 20 listed in the data compiled for this report are all of moderate severity. They include paclitaxel, cabazitaxel, capecitabine, bortezomib, brentuximab vedotin, trastuzumab emtansine, amiodarone, atorvastatin, ethinylestradiol, estradiol, levodopa and ethanol. Alcohol is a well-known concern with nitroimidazoles.

Please refer to the package insert for other warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on model score alone (L5), with no clinical trials or literature. The disease is estrogen-deficiency driven, so an antimicrobial mechanism is unlikely to be relevant. Other top-ranked predictions are similarly unsupported, and the AIDS-related evidence reflects treatment of co-infections, not of HIV.

To proceed, the following is needed:

Package insert warnings and contraindications from the India regulatory source
Detailed mechanism of action data
Evidence that a secondary infectious component is clinically relevant in atrophic vaginitis, before any trial is designed
Assessment of route compatibility, since no vaginal formulation is currently registered
Review of the neuropathy, neutropenia and epilepsy signals for any target population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.